描述
Victoza, containing the active compound liraglutide, is a long-acting GLP-1 receptor agonist widely studied for its impact on glucose metabolism, insulin regulation, and obesity-related mechanisms. This 3ml pre-filled pen delivers 18mg of liraglutide, and is formulated by Novo Nordisk A/S (Denmark) under the NMPA registration number S20160004.
This research-use-only compound is frequently applied in studies on:
-
Type 2 diabetes mellitus pathophysiology
-
Appetite control and energy balance
-
GLP-1 mediated cardiovascular effects
-
Metabolic and endocrine dysfunction models
Note: This product is not intended for clinical, therapeutic, or veterinary use.
Victoza Liraglutide Product Specifications
Parameter | Details |
---|---|
Product Name | Victoza (Liraglutide Injection) |
Generic Name | Liraglutide |
CAS Number | 204656-20-2 |
Molecular Formula | C172H265N43O51 |
Molecular Weight | 3751.2 g/mol |
Dosage Form | Injection (pre-filled pen) |
Strength | 18mg per 3ml |
Concentration | 6mg/ml |
Packaging | 1 pre-filled pen per box (needle not included) |
Approval Number | S20160004 (China) |
Product Code | 86978997002256 |
Manufacturer | Novo Nordisk A/S, Denmark |
Storage Conditions | Store at 2–8°C; protect from light and do not freeze |
Intended Use | For laboratory research only |
Victoza Liraglutide Mechanism of Action & Research Applications
Liraglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking natural incretin hormones to stimulate insulin secretion and suppress glucagon in a glucose-dependent manner. Its extended half-life enables daily injection studies in rodents and other models.
Common research applications include:
-
Obesity and appetite regulation
-
Insulin signaling and glucose tolerance
-
Liver steatosis and nonalcoholic fatty liver disease (NAFLD)
-
Cardiovascular risk and endothelial function
-
Combination therapy with SGLT2 inhibitors, DPP-4 inhibitors, and metformin
Victoza Liraglutide Observed Side Effects in Research Models
-
Nausea and gastric motility disruption
-
Reduced food intake (hypophagia)
-
Delayed gastric emptying
-
Injection site redness or irritation
-
Transient hypoglycemia in combination studies
Victoza Liraglutide Safety & Handling
Use Restriction: Strictly for laboratory research use only. Not for human or veterinary administration.
Handling: Use personal protective equipment (gloves, lab coat). Handle under aseptic conditions.
Storage: Store refrigerated (2–8°C). Avoid direct light and do not freeze.
Disposal: Dispose of contents and containers in accordance with local regulations and institutional biosafety procedures.
Research Use Disclaimer
This product is provided solely for use in laboratory research settings. It is not intended for human, veterinary, or diagnostic applications. Improper use may result in safety or legal consequences. Always follow institutional safety procedures.
评价
目前还没有评价